---
title: "China Resources Pharma's subsidiary China Resources Boya Biology earned 113 million RMB for the year, a decline of 71.6%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280040665.md"
description: "China Resources Pharma announced that its subsidiary, China Resources Boya Biology, achieved an operating revenue of 2.059 billion RMB for the fiscal year 2025, an increase of 18.7% year-on-year. The net profit attributable to shareholders was 113 million RMB, a decline of 71.6%, with earnings per share of 0.22 RMB. A dividend of 0.73 RMB per 10 shares will be distributed"
datetime: "2026-03-22T05:04:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280040665.md)
  - [en](https://longbridge.com/en/news/280040665.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280040665.md)
generator: "portal-rs"
---

# China Resources Pharma's subsidiary China Resources Boya Biology earned 113 million RMB for the year, a decline of 71.6%

China Resources Pharmaceutical (03320.HK) announced that its subsidiary China Resources Boya Biology (300294.SZ) achieved an operating revenue of 2.059 billion RMB for the fiscal year 2025, an increase of 18.7% year-on-year. The net profit attributable to shareholders was 113 million RMB, a decline of 71.6%, with earnings per share of 0.22 RMB. A dividend of 0.73 RMB per 10 shares will be distributed

### Related Stocks

- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)
- [300294.CN](https://longbridge.com/en/quote/300294.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)

## Related News & Research

- [Bank of America Securities Keeps Their Buy Rating on China Resources Pharmaceutical Group Ltd. (640)](https://longbridge.com/en/news/297101685.md)
- [ZAWYA: Emirates Drug Establishment approves first nasal epinephrine spray as alternative to injections for severe allergic reaction](https://longbridge.com/en/news/284603051.md)
- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape](https://longbridge.com/en/news/285930281.md)
- [CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge](https://longbridge.com/en/news/285858047.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**